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Abstract
Background: Etanercept, a soluble tumor necrosis factor receptor, and acitretin have been shown to be effective in
treating psoriasis. Acitretin is widely used in Korea. However, the combination of etanercept plus acitretin has not
been evaluated among Korean patients with psoriasis. The objective of this study was to investigate the efficacy
and safety of combination therapy with etanercept and acitretin in patients with moderate to severe plaque
psoriasis.
Methods: Sixty patients with psoriasis were randomized to receive etanercept 50 mg twice weekly (BIW) for
12 weeks followed by etanercept 25 mg BIW for 12 weeks (ETN-ETN); etanercept 25 mg BIW plus acitretin 10 mg
twice daily (BID) for 24 weeks (ETN-ACT); or acitretin 10 mg BID for 24 weeks (ACT). The primary efficacy
measurement was the proportion of patients achieving 75 % improvement in Psoriasis Area and Severity Index
(PASI 75) at week 24. Secondary end points included 50 % improvement in PASI (PASI 50) at week 24 and clear/
almost-clear by Physician Global Assessment (PGA) at each visit through week 24.
Results: The proportions of patients achieving PASI 75, PASI 50, and PGA clear/almost-clear at week 24 in the ETN-
ETN (52.4, 71.4, and 52.4 %, respectively) and ETN-ACT groups (57.9, 84.2, and 52.6 %, respectively) were higher than
in the ACT group (22.2, 44.4, and 16.7 %, respectively). The incidence of adverse events was similar across all arms.
This was an open-label study with a small number of patients.
Conclusion: In Korean patients with moderate to severe plaque psoriasis, etanercept alone or in combination with
acitretin was more effective than acitretin. All treatments were well tolerated throughout the study.
Trial registration: This study was registered on July 7, 2009 at ClinicalTrials.gov, NCT00936065.
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Background
Psoriasis is a chronic autoimmune condition that af-
fects 1 to 3 % of the general population worldwide
[1–3]. Psoriasis has been associated with an increased
risk for arthritis [4, 5], diabetes [4, 6, 7], cardiovascu-
lar disease [4, 8], depression [4, 9], and poor quality
of life (QoL) [4, 10]. Although there is as yet no cure
[1–3], there are several effective treatments available
to manage the disease [11–16].
In clinical trials, etanercept, a tumor necrosis
factor-alpha (TNFα) inhibitor, has been shown to be
effective in managing psoriasis including improve-
ments in Psoriasis Area Severity Index (PASI) scores
[17–19], Physician’s Global Assessment (PGA) [18,
19], and QoL [19, 20]. Acitretin, a systemic retinoid,
is also effective for the management of psoriasis [21].
Acitretin is frequently used in combination with other
agents (e.g., phototherapy and vitamin D), since aci-
tretin monotherapy is often only moderately effective
[21–24]. Since acitretin is not an immunosuppressive
agent, combination treatment with etanercept may
have a synergistic effect with a low risk of toxicity
[21, 24]. This has been demonstrated in a pilot study
in which the combination of acitretin and low-dose
etanercept was as effective as high-dose etanercept,
and both were significantly more effective than acitre-
tin alone [25]. The purpose of the current study was
to evaluate combination therapy of etanercept plus
acitretin among Korean patients with psoriasis.
Methods
Patients
This study was reviewed and approved by local Institu-
tional Review Boards (Appendix) and was conducted in
compliance with the ethical principles originating in or
derived from the Declaration of Helsinki and in compli-
ance with Good Clinical Practice Guidelines. All patients
provided signed informed consent.
Patients were eligible for study enrolment if they were at
least 18 years of age and had active, clinically stable moder-
ate to severe plaque psoriasis involving ≥10 % body surface
area (BSA) or PASI ≥10. Exclusion criteria included evi-
dence of skin conditions (e.g., eczema) other than psoriasis
that would interfere with evaluations of the effect of study
medication on psoriasis; any rheumatologic disease; prior
exposure to biologic therapies, including etanercept, within
24 weeks of baseline visit; previous history of phototherapy
or any systemic or topical therapy, including acitretin, for
psoriasis within the previous 28 days before baseline visit;
uncontrolled hypertension or diabetes mellitus; any severe
hematologic, cardiovascular, renal, hepatic, or pulmonary
disorders; known contraindication or hypersensitivity to
etanercept or acitretin or their excipients; women who were
pregnant, expecting to become pregnant, or breast-feeding
during the study period; patients with any clinically relevant
concurrent medical conditions such as active or chronic in-
fections, including human immunodeficiency virus, hepa-
titis B virus and hepatitis C virus infections, and active or
recent (within 2 years) tuberculosis; history of cancer (or
carcinoma in situ) other than resected cutaneous basal cell
or squamous cell carcinoma within the past 5 years before
the screening visit; or patients who had received any inves-
tigational drug within 3 months of screening visit.
Study design
In this multicenter, randomized, open-label trial, patients
were randomly assigned to one of three treatment
groups: (a) etanercept 50 mg twice weekly (BIW) for
12 weeks followed by etanercept 25 mg BIW for a fur-
ther 12 weeks (ETN–ETN); (b) etanercept 25 mg BIW
and acitretin 10 mg twice daily (BID) for 24 weeks
(ETN-ACT); (c) acitretin 10 mg BID for 24 weeks (ACT;
Fig. 1). This study was conducted in compliance with
the ethical principles of the Declaration of Helsinki and
the International Conference on Harmonization Good
Clinical Practice Guidelines and registered on Clinical-
Trials.gov, identifier NCT00936065.
The primary endpoint was proportion of patients
achieving ≥75 % improvement from baseline in PASI
score (PASI 75) at week 24. Secondary endpoints in-
cluded the proportion of patients achieving either
PASI 75 or PASI 50 (≥50 % improvement from base-
line) at each visit through week 24, PGA status of
“clear/almost-clear”, and change in percent of BSA in-
volvement from baseline over time.
Statistical analysis
The sample size was calculated assuming 20 patients per
group with a response rate of 35–65 % which would yield
a confidence interval below ± 21.9 %. Further assuming
the response rate difference for primary efficacy endpoints
is 20 % (i.e., 40 vs. 60 %), the 95 % confidence interval
would be approximately ± 30 %.
Statistical analysis was performed using SAS software,
version 9.13. Efficacy evaluation was performed on the
modified intent-to-treat (mITT) and per protocol (PP)
population sets. The mITT population included all ran-
domly assigned patients who received at least one dose of
test medication and had both baseline and on-therapy
PASI evaluations. The PP population included those
members of the mITT population who had no major
protocol violations that could potentially alter the inter-
pretation of the efficacy analysis.
For the outcomes at each visit, the proportions of re-
sponders and the 95 % confidence interval (CI) were de-
termined and the differences between treatment groups
were assessed using Fisher exact test or Chi-square test
with multiple comparisons, if necessary. Kaplan-Meier
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estimations for time to first occurrence of each event were
determined and the log-rank test was used for statistical
testing. For these analyses, no imputation was applied and
the patients who did not experience the event were cen-
sored at the time of last observation.
Basic descriptive statistics are presented for other mea-
sures and the statistical significance of the change from
baseline within the treatment groups was assessed using
the paired t-test or the Wilcoxon signed-rank test. Dif-
ferences in change from baseline between the treatment
groups were assessed using one-way analysis of variance
(ANOVA) or the Kruskal-Wallis test.
Results
All results of this study have been posted on Clinical-
Trials.gov, NCT00936065.
Patients
Of the 60 patients enrolled in this study and randomized to
the three treatment arms, 45 completed the study (Fig. 2).
One patient withdrew from the study after randomization
but before receiving any study medication. Reasons for
study discontinuation included patient request (n = 6),
protocol violation (n = 4), unsatisfactory response (n = 2),
adverse event (AE; n = 2), and lost to follow-up (n = 1). The
baseline demographics were similar across all treatment
arms (Table 1).
Efficacy
The proportion of patients achieving PASI 75 by week 24
in the ETN–ETN and the ETN-ACT groups was numeric-
ally more than twice that observed for the ACT group
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Fig. 2 Patient disposition. ACT, acitretin; ETN, etanercept; mITT, modified intent-to-treat population; PP, per-protocol population
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Table 1 Baseline demographics for the mITT population
Characteristic ETN 50 mg–ETN 25 mg
(n = 21)






Mean age, y (SD) 38.6 (9.5) 35.5 (8.8) 42.4 (12.0) 38.8 (10.3)
Mean height, cm (SD) 169.5 (9.3) 171.7 (5.5) 170.9 (6.8) 170.6 (7.4)
Mean weight, kg (SD) 74.1 (16.0) 74.0 (11.6) 74.2 (9.8) 74.1 (12.7)
Gender, n (%)
Male 16 (76.2 %) 17 (89.5 %) 15 (83.3 %) 48 (82.8 %)
Cigarette status, n (%)
Prior cigarette usage 5 (23.8 %) 5 (26.3 %) 3 (16.7 %) 13 (22.4 %)
Current cigarette usage 10 (47.6 %) 11 (57.9 %) 10 (55.6 %) 31 (53.5 %)
No 6 (28.6 %) 3 (15.8 %) 5 (27.8 %) 14 (24.1 %)
Alcohol status, n (%)
Ex-drinker 2 (9.5 %) 2 (10.5 %) 2 (11.1 %) 6 (10.3 %)
Current-drinker 13 (61.9 %) 13 (68.4 %) 11 (61.1 %) 37 (63.8 %)
No 6 (28.6 %) 4 (21.1 %) 5 (27.8 %) 15 (25.9 %)
Prior therapies for psoriasis, n (%)
Methotrexate 2 (9.5 %) 1 (5.3 %) 0 3 (5.2 %)
Cyclosporine 2 (9.5 %) 2 (10.5 %) 1 (5.6 %) 5 (8.6 %)
PUVA 0 3 (15.8 %) 0 3 (5.2 %)
Othera 12 (57.1 %) 12 (63.2 %) 10 (55.6 %) 34 (58.6 %)
Abbreviations: ACT acitretin, CS clinically significant, ETN etanercept, mITT modified intent-to-treat population, NCS not clinically significant, PUVA psoralen plus
ultraviolet A radiation therapy, SD standard deviation
aIncludes systemic antimycobacterials, medication for treating alimentary tract and metabolism conditions, cardiovascular drugs, respiratory drugs,








































Fig. 3 Proportion of patients achieving PASI 75 at week 24. ACT, acitretin; ETN, etanercept; PASI, Psoriasis Area Severity Index
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(Fig. 3); however, only the pairwise comparison between the
ETN-ACT and ACT groups showed statistical significance
(p = 0.0448).
The proportion of patients achieving PASI 75 increased
at each visit for all treatment arms (Fig. 4a). Of the three
treatment arms, patients in the ETN–ETN group demon-
strated the greatest PASI 75 response during the first
18 weeks, after which their response was comparable to
that observed for the ETN-ACT group. The PASI 75 re-
sponses demonstrated by both of these groups was numer-
ically greater than double that observed for the ACT group.
However, statistically significant treatment difference was
not shown at any time point.
The proportion of patients achieving PASI 50 increased
for all treatment arms (Fig. 4b). The change from baseline
was statistically significant for all treatment arms. A
greater proportion of patients in the ETN–ETN and
ETN-ACT treatment arms achieved PASI 50 at all visits
than did patients in the ACT arm.
The proportion of patients achieving PGA clear/almost-
clear increased for all treatment arms (Fig. 4c). Patients in
the ETN–ETN treatment arm demonstrated the greatest
improvements up to week 12, after which improvements
were similar to those of patients in the ETN-ACT treat-
ment arm. The proportion of patients achieving PGA clear/
almost-clear in the ETN–ETN and ETN-ACT arms was
more than triple that for the ACTarm.
The median time to achieve PASI 75 for patients in
the ETN–ETN arm was 126 days compared with
146 days for patients in the ETN-ACT arm (Table 2).
The median time to achieve PASI 50 was the same
for patients in the ETN–ETN and the ETN-ACT
arms (56 days) and much shorter than for patients in
the ACT arm (126 days). The difference was statisti-
cally significant among the three treatment arms
(PASI 75: p = 0.0448 and PASI 50: p = 0.0033). Add-
itionally, the median time to achieve PGA clear/al-
most-clear was comparable between the ETN–ETN
and ETN-ACT treatment arms (167 and 165 days, re-
spectively). The median time to achieve PASI 75 and
PGA clear/almost-clear could not be determined for
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Fig. 4 Proportion of patients achieving (a) PASI 75, (b) PASI 50, and (c) PGA clear/almost-clear at each visit. ACT, acitretin; ETN, etanercept; PASI,
Psoriasis Area Severity Index; PGA, Physician’s Global Assessment. *p < 0.05; **p < 0.0005
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After 24 weeks of treatment, mean reduction in per-
cent BSA involvement from baseline was greatest in the
ETN–ETN treatment arm (−17.5 %) compared with the
ETN-ACT treatment arm (−16.9 %) and the ACT treat-
ment arm (−10.3 %) at all visits (Fig. 5). The treatment
difference was statistically significant at weeks 4, 8, 12,
and 18, whereas the biggest reduction from baseline was
at week 24 in all three treatment groups.
Safety
Safety was evaluated on all patients who received at
least one dose of study medication. Across the three
treatment arms, 38 (64.4 %) patients reported 85 AEs,
and 27 (45.8 %) patients reported 46 treatment-
related AEs during the study. The overall incidence of
AEs was similar in the three treatment arms (Table 3).
The most common AEs reported across any treatment
arm (Table 4) were pruritus (n = 6, 10.2 %), alopecia
(n = 5, 8.5 %), and dry lips (n = 5, 8.5 %). One patient
in the ACT arm reported a serious AE (severe back
pain), which was determined by the investigator not
to be related to the study treatment. No life-
threatening treatment-emergent AEs occurred during
the study nor were there any changes in laboratory
tests, vital signs, or physical observations that were
considered clinically important (Table 3).
Discussion
Psoriasis is a chronic autoimmune disease and is often as-
sociated with joint inflammation in psoriatic arthritis, a
comorbidity that affects between 10 and 30 % of all people
with psoriasis [2, 3, 26]. Severe cases of psoriasis have been
shown to affect health-related QoL to an extent similar to
the effects of other chronic diseases such as depression,
hypertension, congestive heart failure, or type 2 diabetes
[27].
In multiple trials, etanercept has been shown to be ef-
fective in improving the disease severity of psoriasis and
patient QoL [17–20]. However, treatment with high doses
of etanercept can be expensive [28]. In this context, even
though acitretin monotherapy is often only moderately ef-
fective [21–24], acitretin is widely used to treat psoriasis
and is considered a standard of care in Korea. Further-
more, acitretin has been reported to have malignancy che-
moprevention characteristics [21, 29]. Since acitretin is
not an immunosuppressive agent and may act synergistic-
ally with biologic agents (e.g., etanercept), with a low risk
Table 2 Median time to response









PASI 75 126 (56, 146) 146 (124, NA) NA (127, NA) 0.0448
PASI 50 56 (28, 56) 56 (54, 84) 126 (56, NA) 0.0033
PGA clear/
almost-clear
167 (55, 172) 165 (59, NA) NA (87, NA) 0.3536
Abbreviations: ACT acitretin, CI confidence interval, ETN etanercept, NA not
available, PASI Psoriasis Area Severity Index, PGA Physician’s Global Assessment


































Fig. 5 Change from baseline in percent BSA involvement of psoriasis at each visit. ANCOVA, analysis of covariance; ACT, acitretin; BSA, body
surface area; ETN, etanercept. *p < 0.05; **p < 0.005 (treatment difference tested by ANCOVA)
Lee et al. BMC Dermatology  (2016) 16:11 Page 6 of 9
of toxicity, a combination of etanercept and acitretin could
be a viable treatment option for patients with psoriasis
while keeping treatment affordable and potentially having
additional beneficial effects. The results of a pilot study
[25], a case series [30], and a posthoc review of clinical
treatment practice [24] have suggested that the combin-
ation of etanercept and acitretin is effective and safe for
the treatment of psoriasis. However, the efficacy and safety
of this combination to treat Korean patients with psoriasis
have not been determined until now.
The data presented here demonstrate that the com-
bination of etanercept 25 mg BIW + acitretin 10 mg
BID appears to be as effective for the treatment of
psoriasis in Korean patients as etanercept 50 mg BIW
for 12 weeks followed by etanercept 25 mg BIW.
Furthermore, based on the numerical proportion of
patients achieving efficacy endpoints (i.e., PASI 75,
PASI 50, PGA clear/almost-clear, and reduction in
disease-related BSA), and time to achieve these effi-
cacy endpoints (i.e., time to achieve PASI 75, PASI
50, and PGA clear/almost-clear), both of these treat-
ments appear to be more effective than acitretin
10 mg BID alone. In particular, the PASI 75 response
rate at week 24 for the combined treatment arm
(57.9 %) and the etanercept 50 mg–etanercept 25 mg
arm (52.4 %) was numerically more than twice the
rate of the acitretin 10 mg arm (22.2 %), although the
differences were not statistically significant. However,
unadjusted pairwise comparison showed a significant
difference between the combined treatment group and
acitretin 10 mg group (p = 0.0448). Furthermore, the
proportion of patients achieving PGA clear/almost-
clear in the ETN–ETN and ETN-ACT arms was more
than triple that for the ACT arm. It is possible that
due to the small number of patients, statistical signifi-
cance was not achieved between the ETN–ETN and
ETN-ACT arms and the ACT arm. Our results are
consistent with an earlier Italian, randomized, con-
trolled, pilot trial that showed PASI 75 response at
week 24 was achieved by 45 % of the patients in the
etanercept 25 mg BIW group, 44 % of the patients
treated with etanercept 25 mg + acitretin, and 30 % of
the patients in the acitretin 0.4 mg-kg−1 daily group.
However, etanercept 25 mg BIW is not commonly ef-
fective in treating plaque psoriasis. Consequently, in
our study, we treated patients at a higher initial dose
of etanercept (50 mg BIW) and adjusted the dose
downward to 25 mg BIW as the patients improved –
a treatment regimen that we believe better reflects
the real-world conditions.
These data demonstrate that the combination of etaner-
cept with acitretin is just as effective as etanercept alone
at week 24. However, patients treated with etanercept
alone achieved the efficacy outcome endpoints faster than
did patients receiving the combination. Treatment with
etanercept alone may be preferred by patients wanting a
Table 3 Summary of treatment-emergent adverse events

















Patients with TEAEs, n (%) 14 (66.7 %) 14 (70.0 %) 10 (55.6 %) 38 (64.4 %) 9 (42.9 %) 10 (50.0 %) 8 (44.4 %) 27 (45.8 %)
Total number of TEAEs 22 38 25 85 11 22 13 46
Patients with SAEs, n (%) 0 (0.0 %) 0 (0.0 %) 1 (5.6 %) 1 (1.7 %) 0 (0.0 %) 0 (0.0 %) 0 (0.0 %) 0 (0.0 %)
Total number of SAEs 0 0 1 1 0 0 0 0
Permanent discontinuation
due to AE, n (%)
1 (4.8 %) 0 1 (5.6 %) 2 (3.4 %) – – – –
Abbreviations: ACT acitretin, AE adverse event, ETN etanercept, SAE serious adverse event, TEAE treatment-emergent adverse event
Table 4 Incidence of TEAEs in ≥10 % of patients in any
treatment arm










Skin and subcutaneous tissue disorders
Pruritus 3 (14.3 %) 2 (10.0 %) 1 (5.6 %) 6 (10.2 %)
Alopecia – 4 (20.0 %) 1 (5.6 %) 5 (8.5 %)
Skin exfoliation – 2 (10.0 %) 1 (5.6 %) 3 (5.1 %)
Gastrointestinal disorders
Dry lip – 3 (15.0 %) 2 (11.1 %) 5 (8.5 %)
Cheilitis – 2 (10.0 %) 2 (11.1 %) 4 (6.8 %)





1 (4.8 %) 2 (10.0 %) – 3 (5.1 %)
Blood bilirubin
increased
– 2 (10.0 %) – 2 (3.4 %)
Musculoskeletal and connective tissue disorders
Myalgia – – 2 (11.1 %) 2 (3.4 %)
Vascular disorders
Hypertension – 2 (10.0 %) – 2 (3.4 %)
Abbreviations: ACT acitretin, ETN etanercept, TEAE treatment-emergent adverse event
Lee et al. BMC Dermatology  (2016) 16:11 Page 7 of 9
more rapid resolution of their disease whereas treatment
with the combination of these two drugs may be prefera-
ble for others without sacrificing efficacy or safety. The
treating physician will need to consider these options in
consultation with the patient to determine the optimum
treatment regimen.
All treatments appeared to be safe and well tolerated by
the patients. The incidence and severity of AEs appeared to
be similar across all treatment arms. No life-threatening
AEs were reported and no patient-reported SAEs that were
related to study treatment. For patients with skin diseases,
these results are important in terms of satisfaction with
treatment and improvement of signs and symptoms of the
disease, and could potentially affect their QoL.
Conclusions
In this study, the treatment of psoriasis with the com-
bination therapy of etanercept and acitretin substantially
reduced the severity of disease in Korean patients over a
period of 24 weeks. These results suggest that etanercept
could be added to acitretin to treat Korean patients with
psoriasis, especially when the disease is resistant or
responding inadequately to topical treatment or photo-
therapy. Combination therapy of etanercept and acitre-
tin, and etanercept alone, are both effective and well
tolerated; however, the choice of treatment may depend
on finding a balance between the costs of the treatment
versus the rapidity with which patients desire to experi-
ence the benefits of the treatment.
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